Nonetheless, numerous studies have shown that EVs derived from tumor cells are capable of migrating tumor associated antigens to the host cells, thus stimulating anti-tumor immunity by activating CD8(+) and CD4(+) T cells. This evidence concerns the gene CD8A and neoplasm.